Arvinas (ARVN) Revenue Growth (1y) (2018 - 2026)
Powered by 
Analysis
Arvinas (ARVN) Revenue Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 12.45% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 16.73% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 59.71% |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 2.11% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 29.63% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 66.86% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 16.50% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 296.11% |
| 10 | Arvinas | 609.44 Mn | 41.54 Mn | - | 1,014.73% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,014.73% |
| Mar 31, 2026 | -91.74% |
| Dec 31, 2025 | -83.95% |
| Sep 30, 2025 | -59.08% |
| Jun 30, 2025 | -70.72% |
| Mar 31, 2025 | 646.25% |
| Dec 31, 2024 | 237.35% |
| Sep 30, 2024 | 195.95% |
| Jun 30, 2024 | 40.37% |
| Mar 31, 2024 | -22.15% |
| Dec 31, 2023 | -214.02% |
| Sep 30, 2023 | 4.22% |
| Jun 30, 2023 | 61.24% |
| Mar 31, 2023 | 22.64% |
| Dec 31, 2022 | 13.86% |
| Sep 30, 2022 | 256.99% |
| Jun 30, 2022 | 514.55% |
| Mar 31, 2022 | 381.82% |
| Dec 31, 2021 | 425.66% |
| Sep 30, 2021 | 22.42% |